The experiment conducted by Wei44 proved that GCH1 induced immunosuppression through a 5-HTP-AHR-ID01-dependent mechanism, and that the combination of metabolic intervention and immunotherapy of this pathway might be a promising strategy for the treatment of triple-negative breast cancer (TNBC), and the GCH1 inhibitor could be used as an analgesic45. The gene discussed is AHR; the disease is triple-negative breast carcinoma.